[
  {
    "ts": null,
    "headline": "Big pharma's multiple looming patent cliffs: What to know",
    "summary": "The pharmaceutical industry is staring down a major patent cliff, with key drugs from Merck (MRK), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ) set to lose exclusivity by 2030. Yahoo Finance Senior Reporter Anjalee Khemlani and Freedom Capital Markets chief global strategist Jay Woods join Market Domination host Josh Lipton to discuss the industry's risks and how Wall Street is responding. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=6c19949832175d329a0625c8a4547b90492148f57fabbb3a53416d99530dda68",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752267366,
      "headline": "Big pharma's multiple looming patent cliffs: What to know",
      "id": 135885558,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The pharmaceutical industry is staring down a major patent cliff, with key drugs from Merck (MRK), Bristol Myers Squibb (BMY), and Johnson & Johnson (JNJ) set to lose exclusivity by 2030. Yahoo Finance Senior Reporter Anjalee Khemlani and Freedom Capital Markets chief global strategist Jay Woods join Market Domination host Josh Lipton to discuss the industry's risks and how Wall Street is responding. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=6c19949832175d329a0625c8a4547b90492148f57fabbb3a53416d99530dda68"
    }
  },
  {
    "ts": null,
    "headline": "Why Bristol-Myers Squibb (BMY) Shares Are Sliding Today",
    "summary": "Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a cautious analyst note from UBS highlighting significant upcoming expenses and other headwinds. Ahead of its second-quarter earnings report, UBS reiterated its \"Neutral\" rating on the stock. The firm's note pointed to several challenges, including an expected $1.5 billion expense for in-process research and development (IPR&D) related to a collaboration with BioNTech. This charge is anti",
    "url": "https://finnhub.io/api/news?id=a6fd0aa8e2ea21981de2e2ef4e0455b40f152d81f7b87f1e04f0d421a6933185",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752262252,
      "headline": "Why Bristol-Myers Squibb (BMY) Shares Are Sliding Today",
      "id": 135883797,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Shares of biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) fell 3.5% in the afternoon session after a cautious analyst note from UBS highlighting significant upcoming expenses and other headwinds. Ahead of its second-quarter earnings report, UBS reiterated its \"Neutral\" rating on the stock. The firm's note pointed to several challenges, including an expected $1.5 billion expense for in-process research and development (IPR&D) related to a collaboration with BioNTech. This charge is anti",
      "url": "https://finnhub.io/api/news?id=a6fd0aa8e2ea21981de2e2ef4e0455b40f152d81f7b87f1e04f0d421a6933185"
    }
  },
  {
    "ts": null,
    "headline": "Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys",
    "summary": "Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys",
    "url": "https://finnhub.io/api/news?id=f449d5ea2dfbea4cff466396007d65a11120af381c1f5fa3562ac5ac831ba067",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752254633,
      "headline": "Dogs Of The S&P 500: 14 Ideal 'Safer' July Dividend Buys",
      "id": 135884821,
      "image": "",
      "related": "BMY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=f449d5ea2dfbea4cff466396007d65a11120af381c1f5fa3562ac5ac831ba067"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
    "summary": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=367b4e8158f8229e0c9b55f4079cc2af583bb7f2630aa7f85021bc9cc6ef7929",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752251400,
      "headline": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
      "id": 135952252,
      "image": "",
      "related": "BMY",
      "source": "MarketWatch",
      "summary": "Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=367b4e8158f8229e0c9b55f4079cc2af583bb7f2630aa7f85021bc9cc6ef7929"
    }
  },
  {
    "ts": null,
    "headline": "ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?",
    "summary": "AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.",
    "url": "https://finnhub.io/api/news?id=34a4b433845c069154092e555ae20c3cf368a16b00d08767dbc941be64af250b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752242400,
      "headline": "ABBV or BMY: Which Biopharma Giant Has Better Prospects for Now?",
      "id": 135883478,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "AbbVie edges ahead of Bristol Myers with strong Skyrizi and Rinvoq growth, offsetting Humira declines and portfolio headwinds.",
      "url": "https://finnhub.io/api/news?id=34a4b433845c069154092e555ae20c3cf368a16b00d08767dbc941be64af250b"
    }
  },
  {
    "ts": null,
    "headline": "2 Top Stocks Down 16% and 17% This Year to Buy and Hold",
    "summary": "Merck and Bristol Myers Squibb are facing challenges due to recent (and future) patent cliffs.  Here are two great examples to consider: Merck (NYSE: MRK) and Bristol Myers Squibb (NYSE: BMY).  Merck is fast approaching the loss of patent exclusivity for Keytruda, its biggest growth driver by far.",
    "url": "https://finnhub.io/api/news?id=afbd329b7a05e5036a80cf0b264fa1ee1f28a845edaf921f67c1abd727729334",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752226560,
      "headline": "2 Top Stocks Down 16% and 17% This Year to Buy and Hold",
      "id": 135876740,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Merck and Bristol Myers Squibb are facing challenges due to recent (and future) patent cliffs.  Here are two great examples to consider: Merck (NYSE: MRK) and Bristol Myers Squibb (NYSE: BMY).  Merck is fast approaching the loss of patent exclusivity for Keytruda, its biggest growth driver by far.",
      "url": "https://finnhub.io/api/news?id=afbd329b7a05e5036a80cf0b264fa1ee1f28a845edaf921f67c1abd727729334"
    }
  },
  {
    "ts": null,
    "headline": "Psoriatic Arthritis Market Report 2025-2035 | Competitive Analysis of AbbVie, UCB, Pfizer, Johnson & Johnson, Eli Lilly and Co, Bristol-Myers Squibb, Affibody, Amgen, Boehringer Ingelheim, Sun Pharma",
    "summary": "Psoriatic arthritis is a chronic inflammatory disease linked to psoriasis, characterized by joint inflammation, pain, and swelling. Affecting both men and women, typically between ages 30-50, it's driven by rising autoimmune diseases and emerging biologic treatments like TNF and JAK inhibitors. Key market developments include advances in early diagnosis tools and precision medicine, tailoring treatments to genetic profiles. While growth is challenged by high biologic costs and diagnosis complexi",
    "url": "https://finnhub.io/api/news?id=6d6c2f9bc2075c0b32e4585440d25a0af4a43c7f00592f693f00f0d680f64571",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1752220860,
      "headline": "Psoriatic Arthritis Market Report 2025-2035 | Competitive Analysis of AbbVie, UCB, Pfizer, Johnson & Johnson, Eli Lilly and Co, Bristol-Myers Squibb, Affibody, Amgen, Boehringer Ingelheim, Sun Pharma",
      "id": 135876885,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "Psoriatic arthritis is a chronic inflammatory disease linked to psoriasis, characterized by joint inflammation, pain, and swelling. Affecting both men and women, typically between ages 30-50, it's driven by rising autoimmune diseases and emerging biologic treatments like TNF and JAK inhibitors. Key market developments include advances in early diagnosis tools and precision medicine, tailoring treatments to genetic profiles. While growth is challenged by high biologic costs and diagnosis complexi",
      "url": "https://finnhub.io/api/news?id=6d6c2f9bc2075c0b32e4585440d25a0af4a43c7f00592f693f00f0d680f64571"
    }
  }
]